Every round on record, with the sources behind each and the investors on them.
A spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics
undecimalbio.comCambridge, UKBiotech
7 sources
Source 2 reports €16 million ($18 million), but the company's release states $18 million USD and is preferred. Source 1's Cambridge/Israel dateline is not treated as headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $18M | 2026-10-13 | 4BIO Capital, IQ Capital | 7 outlets. #11 in Trending |
7 sources [ VERIFIED ] read against 4 of 7 sources Source 2 reports €16 million ($18 million), but the company's release states $18 million USD and is preferred. Source 1's Cambridge/Israel dateline is not treated as headquarters. | ||||
Undecimal pairs massive-scale combinatorial chemistry with transformer-based AI to guide siRNA therapeutics into the tissues that need them.
Undecimal targets what its site and launch coverage describe as the central bottleneck for siRNA: delivering it beyond the liver to the right tissue and cell. Its $18 million seed bet funds the DELiveri platform, initial kidney and vascular renovascular programs, and team expansion, while the company says the platform is validated in vivo and that it has several undisclosed big-pharma research collaborations.